Abstract:Age-dependent neurodegenerative diseases progressively form aggregates containing both shared components (e.g., TDP-43, phosphorylated tau) and proteins specific to each disease. We investigated whether diverse neuropathies might have additional aggregation-prone proteins in common, discoverable by proteomics. Caenorhabditis elegans expressing unc-54p/Q40::YFP, a model of polyglutamine array diseases such as Huntington's, accrues aggregates in muscle 2-6days posthatch. These foci, isolated on antibody-coupled magnetic beads, were characterized by high-resolution mass spectrometry. Three Q40::YFP-associated proteins were inferred to promote aggregation and cytotoxicity, traits reduced or delayed by their RNA interference knockdown. These RNAi treatments also retarded aggregation/cytotoxicity in Alzheimer's disease models, nematodes with muscle or pan-neuronal A(1-42) expression and behavioral phenotypes. The most abundant aggregated proteins are glutamine/asparagine-rich, favoring hydrophobic interactions with other random-coil domains. A particularly potent modulator of aggregation, CRAM-1/HYPK, contributed <1% of protein aggregate peptides, yet its knockdown reduced Q40::YFP aggregates 7286% (P<10(-6)). In worms expressing A(1-42), knockdown of cram-1 reduced -amyloid 60% (P<0.002) and slowed age-dependent paralysis >30% (P<10(-6)). In wild-type worms, cram-1 knockdown reduced aggregation and extended lifespan, but impaired early reproduction. Protection against seeded aggregates requires proteasome function, implying that normal CRAM-1 levels promote aggregation by interfering with proteasomal degradation of misfolded proteins. Molecular dynamic modeling predicts spontaneous and stable interactions of CRAM-1 (or human orthologs) with ubiquitin, and we verified that CRAM-1 reduces degradation of a tagged-ubiquitin reporter. We propose that CRAM-1 exemplifies a class of primitive chaperones that are initially protective and highly beneficial for early reproduction, but ultimately impair aggregate clearance and limit longevity.

Propagation of Aggregated P53: Cross-reaction and Coaggregation Vs. Seeding

Self-Aggregation And Coaggregation Of The P53 Core Fragment With Its Aggregation Gatekeeper Variant

First-Order Rate-Determining Aggregation Mechanism Of P53 And Its Implications

Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors

Multisite Aggregation Of P53 And Implications For Drug Rescue

Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.

Kinetic Mechanism of P53 Oncogenic Mutant Aggregation and Its Inhibition

Mechanism Of Initiation Of Aggregation Of P53 Revealed By Phi-Value Analysis

Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets

p53 amyloid aggregation in cancer: function, mechanism, and therapy

Oncogenic Phase Transitions: How Mutant p53 Drives Amyloid Formation in p63 and p73 Liquid Droplets

Interdiction in the Early Folding of the p53 DNA-Binding Domain Leads to Its Amyloid-Like Misfolding

Mechanistic Insight into the Destabilization of P53td Tetramer by Cancer-Related R337H Mutation: a Molecular Dynamics Study.

Conformational Stability and Dynamics of the Cancer‐associated Isoform Δ133p53β Are Modulated by P53 Peptides and P53‐specific DNA

The Status of p53 Oligomeric and Aggregation States in Cancer

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Δ133p53 and Δ160p53 isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation

The guardian of the genome meets a viral master gene regulator at a biomolecular condensate

Multiscale simulations reveal the driving forces of p53C phase separation accelerated by oncogenic mutations

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.

Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates